[SM-108].
The purpose of this paper is to analyze the available data on SM-108 (4-carbamoylimidazolium 5-olate) with respect to its clinical usefulness, optimal method of administration, and side effects. Successful remission induction was achieved in atypical leukemia using low dose SM-108. To analyze the action of SM-108, freshly isolated leukemic cells and cells from human leukemic cell line were cultured in the presence of SM-108. Minimal evidence of differentiation induction was observed. SM-108 in a higher dose, alone or in combination with other drugs was advocated for the treatment of adult ALL. Side effect including myelotoxicity and gastrointestinal toxicity was minimal.
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy; D002460:Cell Line; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D007938:Leukemia / Q000188:drug therapy* / Q000473:pathology; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy; D013274:Stomach Neoplasms / Q000188:drug therapy; D014410:Tumor Stem Cell Assay; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy
D000970:Antineoplastic Agents; D007093:Imidazoles; C033758:4-carbamoylimidazolium 5-olate